Press releases
- Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- Theravance Biopharma to Participate in an Upcoming Investor Conference
- Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Key statistics
On Thursday, Theravance Biopharma Inc (0TB:DEU) closed at 8.05, 8.05% above its 52-week low of 7.45, set on May 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.15 |
---|---|
High | 8.25 |
Low | 7.95 |
Bid | 8.05 |
Offer | 8.25 |
Previous close | 8.10 |
Average volume | 56.40 |
---|---|
Shares outstanding | 48.63m |
Free float | 41.56m |
P/E (TTM) | -- |
Market cap | 419.70m USD |
EPS (TTM) | -0.861 USD |
Data delayed at least 15 minutes, as of Jun 06 2024.
More ▼